Multiple epidemiological studies have shown that depression is the most frequent comorbid psychiatric disorder in patients with epilepsy. Prevalence rates range from 20% to 55% in patents with recurrent seizures and 6% to 8% in patients with well-controlled seizures. In addition, suicide is one of the most common causes of death in patients with epilepsy; it was found to be almost 10 times more frequent in these patients than in the general population. In a study carried out in a group of patients with refractory epilepsy admitted to a video-electroencephalogram monitoring unit, it was found 50% of the patients were depressed, 19% had suicidal ideation, and only 17% were being treated with antidepressant medications. Despite the high prevalence of depression and suicide risk, depression often goes unrecognized and untreated in these patients. Reasons for this include:

• Treating physicians pay attention only to seizure control and fail to inquire about the presence of psychiatric symptoms;



• Patients are hesitant to report mood changes, and when they do, they tend to minimize them out of fear of being thought of as crazy;



• Physicians and patients often consider symptoms of depression to be a normal adaptation process to epilepsy and its associated problems; and



• A fear among clinicians that antidepressant drugs can exacerbate the underlying seizure disorder prevents many patients from receiving treatment even when the need for antidepressant treatment is recognized.

The goal of this article is to highlight the importance of recognizing, preventing and treating depression in patients with epilepsy.

Associated Risk Factors

Seizure-related factors Many investigators have tried to find an association between depression and epilepsy with respect to age of onset and seizure type, frequency, and duration. Depression has been identified more frequently in patients with seizures involving limbic structures (predominantly temporal and frontal lobes) and less often in patients with generalized seizure disorders. Laterality of seizure focus also has been considered as a possible risk factor, with seizure disorders of left hemispheric origin being more likely to be associated with depression. This association has been questioned by several investigators, however. There is evidence that seizures originating in or propagating to the frontal lobes increase risk of depression. For instance, patients with left temporal focus and depression have been found to display bilateral inferior frontal hypometabolism on both positron emission tomography (PET) and single proton emission computed tomography (SPECT) studies. In fact, decreased frontal metabolism on PET and SPECT has been found in primary depression.

Do depression and epilepsy share common pathogenic mechanisms? Twenty-six centuries ago, Hippocrates was the first to suggest a bidirectional relationship between epilepsy and depression:

• Melancholics ordinarily become epileptics, and epileptics melancholics: what determines the preference is the direction the malady takes; if it bears upon the body, epilepsy, if upon the intelligence, melancholy.



• This observation has been supported by population-based, controlled studies published in the past 10 years. Forsgren and Nystrom (1990) conducted a population-based, case-controlled study of patients with newly diagnosed epilepsy in Sweden. They discovered that patients with epilepsy were six times more likely than controls to have experienced a history of depression prior to the onset of the seizure disorder. In a separate study, Hesdorffer et al. (2000) conducted a population-based, case-controlled investigation of the prevalence of new-onset epilepsy among adults ages 55 and older and showed that compared to controls, patients were 3.7 times more likely to have had a history of depression prior to the onset of their seizure disorder. These researchers controlled for the impact of medical therapies for depression on seizure occurrence.



• These data do not suggest that depression causes epilepsy or vice versa, but they do suggest that the two disorders may share common pathogenic mechanisms. Indeed, epilepsy and depression may share common pathogenic mechanisms mediated by abnormal serotonergic, noradrenergic, -aminobutyric acid (GABA)-ergic and dopaminergic secretion in the central nervous system. In primary depression, decreased activity of these neurotransmitters has been identified as one of the pivotal pathogenic mechanisms and the basis for antidepressant pharmacologic treatment. In animal models of epilepsy using the genetically epilepsy-prone rat, decreased activities of serotonin and norepinephrine have been shown to facilitate the kindling process, exacerbate the seizure severity and intensify seizure predisposition. Other common pathogenic mechanisms for primary depression and epilepsy include disturbance of mesial temporal structures, particularly amygdala and hippocampal formation, which have been found to be atrophic in both disorders.

Psychosocial factors Patients with epilepsy are subjected to discrimination and lack of acceptance. Significant risk factors for the development of depression include the stigma of having epilepsy; the lack of social support; the need to make significant adjustments in lifestyle, such as giving up driving privileges or having to change jobs; and the limited educational and employment opportunities. The individual's sense of lack of control over their life may result in overall fear of seizures and agoraphobic behavior that may not correlate with the actual severity of seizure activity. In addition, sexual dysfunction has been a very prevalent problem among patients with epilepsy, with rates ranging from 14% to 66%. Although biologic and medication factors are largely causative, they clearly facilitate the development of decreased self-esteem and depression.

Latrogenic factors Antiepileptic drugs can cause psychiatric symptoms, especially depression. Phenobarbital (Luminal), felbamate (Felbatol), primidone (Mysoline), tiagabine (Gabitril), vigabatrin (Sabril), topiramate (Topamax) and levetiracetam (Keppra) are known to cause depressive episodes. In addition, cognitive side effects associated with some of these drugs (e.g., topiramate) are closely associated with previous or current history of depression. Carbamazepine (Tegretol) and valproic acid (Depakene) are anti-epileptic drugs with mood-stabilizing effects, but can occasionally cause depressive symptoms as well.

Depression and other psychiatric complications have been seen after epilepsy surgery and especially following an anterior temporal lobectomy for the treatment of pharmacoresistant temporal lobe epilepsy. It is actually not unusual to see mood lability within the initial six weeks after the surgery. Most of the time these symptoms subside, but in up to 30% of the patients, overt symptoms of depression become evident within the first six months. Patients with prior history of depression are at greater risk. The development of this depression is independent of the postsurgical seizure control.

Depression in patients with epilepsy can be the expression of a relatively rare phenomenon known as forced normalization. It consists of the development of psychiatric symptoms following the cessation of seizures in patients whose seizures had failed to be controlled for a long time. Worsening of interictal depression in patients when seizure control is achieved may also be an expression of this phenomenon.

Clinical Expressions

Depressive symptoms and disorders can be classified according to their temporal relation to seizure occurrence. Depressive symptoms can present during the 48 to 72 hours preceding a seizure (pre-ictal symptoms of depression), they can be an expression of an actual seizure (ictal symptoms of depression) or can occur within 120 hours after a seizure (postictal symptoms of depression). Symptoms that precede or follow are referred to as peri-ictal symptoms. Depression can also occur unrelated to the seizure occurrence (interictal depression). Often, patients experience symptoms of depression during both peri-ictal and interictal periods with an exacerbation in severity of symptoms during the postictal period.

Pre-ictal symptoms There are a few reports in the literature of pre-ictal depression, which typically presents as a cluster of dysphoric symptoms for hours or up to three days before the onset of seizures. Studies revealed mood changes over 56 days in 27 patients who were asked to rate their mood daily. Mood ratings pointed to symptoms of dysphoria, anxiety and irritability three days before a seizure in 22 patients. This change in mood was more accentuated during the 24 hours preceding the seizure. It should be noted that in children, these dysphoric moods take the form of irritability, poor frustration tolerance, motor hyperactivity and aggressive behavior.

Ictal symptoms Ictal symptoms of depression are the expressions of a simple partial seizure (aura) in which the symptoms of depression are its sole (or predominant) semiology. It has been estimated that psychiatric symptoms occur in 25% of auras; 15% of these involve affect or mood changes. Ictal depression ranked second after anxiety/fear as the most common type of ictal affect in one study. When mood changes represent the only clinical expression of simple partial seizures, it may be difficult to recognize them as epileptic phenomena. Typically, they are brief, are stereotypical, occur out of context with the patient's activity and are associated with other ictal phenomena. The most common symptoms include feelings of anhedonia (inability to experience pleasure in anything), guilt and suicidal ideation. More typically ictal symptoms of depression are followed by alteration of consciousness as the ictus evolves from a simple to a complex partial seizure.

Postictal symptoms Recognized for a very long time, postictal symptoms of depression have been recently studied in systematic matter in a study completed in our center, where we investigated the presence of postictal psychiatric symptoms in 100 consecutive patients with poorly controlled partial seizure disorders. Patients were given a 42-item questionnaire designed to identify psychiatric symptoms occurring in the postictal period, defined as 72 hours following recovery of consciousness from the last seizure. The following symptoms of depression were investigated: anhedonia, irritability, poor frustration tolerance, feelings of hopelessness and hopelessness, suicidal ideation, feelings of guilt and self-deprecation, and crying bouts. Five neuro-vegetative symptoms (changes in pattern of sleep, appetite and sexual drive) were analyzed separately, as they are common postictal symptoms not associated with symptoms of depression.

A total of 43 patients (43%) experienced a median of five postictal symptoms of depression after more than 50% of their seizures. Patients estimated a median duration of 24 hours in two-thirds of the symptoms they experienced. Thirty-five patients experienced at least two postictal symptoms, with a minimum duration of 24 hours; in 13 of these patients, at least seven symptoms clustered to mimic symptoms of a major depression lasting 24 hours or longer. Thirteen patients reported habitual postictal suicidal ideations. Thirteen patients exclusively experienced symptoms of depression, whereas in the other 30 patients, we identified concurrent postictal symptoms of anxiety and a combination of depression, psychosis and anxiety. It should be noted that postictal symptoms of depression were significantly associated with more postictal cognitive deficits.

Clearly, these data show that postictal symptoms of depression are relatively common in a sample of patients with poorly controlled epilepsy. It remains to be investigated whether this observation applies to patients with rare seizures. It should be kept in mind that the symptoms of postictal depression can last up to two weeks after the seizure occurrence. At times, this can lead to suicide attempts; therefore, close follow up of patients with known postictal depression is necessary.

Interictal depression Interictal depression is the most commonly recognized presentation of affective disorders among patients with epilepsy. Interictal depression can present as major depressive disorder or any of the other mood disorders included in the DSM-IV classification. In our opinion, however, a large number of patients with epilepsy do not meet DSM-IV criteria for these mood disorders, rather they have pleomorphic cluster of symptoms of depression with a chronic course that is interrupted by recurrent symptom-free periods of hours to several days duration. This clinical presentation closely resembles a dysthymic disorder and refers to this atypical form of depression as interictal dysphoric disorder. Almost one-third to one-half of patients with epilepsy suffer from interictal dysphoric disorder of sufficient severity to require pharmacologic treatment. It is described as the interictal dysphoric disorder as a chronic dysthymic state in which symptoms tend to occur intermittently and are intermixed with brief euphoric moods, explosive irritability, anxiety and somatoform symptoms (e.g., anergia, atypical pain and insomnia), which have been considered as depressive equivalents. Despite the fact that interictal depression presenting as interictal dysphoric disorder is so prevalent among our patients, it usually goes unreported by patients and unrecognized by clinicians. Patients eventually assume that their symptoms reflect a natural state that is part of their epilepsy. Physicians overwhelmed with the goal to achieve seizure control very often miss detecting symptoms of depression, even in patients they have followed for a long time. Clinicians should carefully inquire about symptoms of depression as an integral part of their evaluation of seizure disorder.

Treatment

Many clinicians are reluctant to use antidepressant medications in patients with known seizure disorder because of fear that the antidepressant drugs can worsen the seizure disorder. However, is that a legitimate concern? Antidepressants have been associated with increased risk of seizure in nonepileptic patients at high plasma serum concentrations or when given at rapid dose increments. Other risk factors include known CNS pathology, abnormal EEG, and personal and family history of epilepsy. If this is the case, then do antiepileptic drugs protect patients with epilepsy from the proconvulsant properties of these drugs?

Psychotherapy is an important addition to pharmacological treatment. Counseling and psychotherapy can be very useful in helping the patient deal with the stressors and limitations of living with epilepsy. Patients involved in psychotherapy not only improve in scales of depression and anxiety but also show a decline in seizure frequency. Clinicians should keep in mind that in patients with refractory epilepsy, mood disorders and adverse events have a greater impact on patients' quality of life than the actual seizure frequency or severity. Therefore, treatment of the seizure disorder without treating the eventual comorbid depression is incomplete and inappropriate.

Conclusion

Depression is a common comorbidity in patients with epilepsy. Depression is frequently unrecognized and untreated by the physicians taking care of patients with epilepsy. The depression that occurs in patients with epilepsy is not necessarily as easy to recognize when not presenting as major depression; therefore, clinicians have to inquire about symptoms of depression when evaluating patients with epilepsy. The treatment of depression is of high importance for a patient with epilepsy, since it is strongly associated with the patient's quality of life. ...by Antoaneta Balabanov, M.D., and Andres M. Kanner, M.D, Psychiatric Times

Active Living ~ Many Areas of Interest

The Human Nature Daily Review

Sexual Health and Sexually Transmitted Infections "TALK TO ME" "Talk To Me" is a sexuality education program designed to help parents to talk to their children about sexuality. It has been developed with emphasis on teenage perspectives. It was initially developed by the Cape Breton Wellness Centre and the University College of Cape Breton, in collaboration with parents and funded by Health Canada. "Talk To Me" was then adapted into French and revised to address the recommendations of parents who had participated in a pilot project. The program's intent is to make parents more aware of adolescent needs and difficulties related to sexuality, to develop their communication skills and to help them become more knowledgeable and more 'askable' parents. (read on)

Go Smoke Free! More than 45,000 people will die prematurely this year in Canada due to tobacco use -- at least 1,000 of them will be non-smokers. Tobacco. We can live without it. (please read on)

Edition No. 12
Insight EFAP International